Windtree Therapeutics Reports Executive Changes and Compensation Updates
Ticker: WINTW · Form: 8-K · Filed: Feb 16, 2024 · CIK: 946486
| Field | Detail |
|---|---|
| Company | Windtree Therapeutics Inc /De/ (WINTW) |
| Form Type | 8-K |
| Filed Date | Feb 16, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-changes, compensation, corporate-governance
TL;DR
**Windtree Therapeutics just filed an 8-K about executive changes and compensation, so keep an eye on their leadership and strategy!**
AI Summary
Windtree Therapeutics, Inc. filed an 8-K on February 16, 2024, reporting an event that occurred on February 15, 2024. The filing pertains to Item 5.02, which covers the departure or election of directors or certain officers and compensatory arrangements. This indicates potential changes in leadership or executive compensation at the company.
Why It Matters
Changes in executive leadership or compensation can signal strategic shifts, financial health, or future direction for Windtree Therapeutics, impacting investor confidence and company performance.
Risk Assessment
Risk Level: medium — Changes in executive leadership can introduce uncertainty regarding future company direction and stability, posing a medium risk.
Key Players & Entities
- Windtree Therapeutics, Inc. (company) — Registrant
- February 15, 2024 (date) — Date of earliest event reported
- February 16, 2024 (date) — Filing date
- 001-39290 (other) — Commission File Number
- Delaware (other) — State of incorporation
FAQ
What was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on February 15, 2024.
What is the name of the registrant company for this 8-K?
The registrant company for this 8-K is Windtree Therapeutics, Inc.
What specific item number of Form 8-K is addressed in this filing?
This filing addresses Item 5.02, which covers 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers'.
When was this 8-K form filed with the SEC?
This 8-K form was filed with the SEC on February 16, 2024.
In which state is Windtree Therapeutics, Inc. incorporated?
Windtree Therapeutics, Inc. is incorporated in Delaware.
Filing Stats: 554 words · 2 min read · ~2 pages · Grade level 11.9 · Accepted 2024-02-16 17:07:43
Key Financial Figures
- $0.001 — h registered Common Stock , par value $0.001 per share WINT The Nasdaq Capital Ma
Filing Documents
- wint20240215_8k.htm (8-K) — 24KB
- 0001437749-24-004614.txt ( ) — 153KB
- wint-20240215.xsd (EX-101.SCH) — 3KB
- wint-20240215_def.xml (EX-101.DEF) — 11KB
- wint-20240215_lab.xml (EX-101.LAB) — 15KB
- wint-20240215_pre.xml (EX-101.PRE) — 11KB
- wint20240215_8k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Dated: February 16, 2024 Windtree Therapeutics, Inc. By: /s/ Craig E. Fraser Name: Craig E. Fraser Title: President and Chief Executive Officer